Trial Profile
A Randomized, Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib, and Dexamethasone (RVD) to High-Dose Treatment With Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients Up to 65 Years of Age
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 21 Dec 2023
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Bortezomib (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary) ; Melphalan
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms DETERMINATION; DFCI 10-106
- 12 Dec 2023 Results of an exploratory analysis assessing outcomes with RVd-alone vs RVd+ASCT in AA and White patients from two clinical trials: DETERMINATION and GRIFFIN presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 11 Dec 2023 According to Dana-Farber Cancer Institute media release, data from the study were presented in a poster session at the 65th American Society of Hematology Annual Meeting and Exposition in San Diego, CA, on Monday, December 11, 2023.
- 11 Dec 2023 Results of subgroup analysis presented in the Dana-Farber Cancer Institute Media Release.